CPC A61K 31/496 (2013.01) [A61K 9/0019 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01)] | 35 Claims |
1. A method of treating a subject afflicted with cancer, comprising administering to the subject a 0.5 mg/m2, 0.83 mg/m2, 1.25 mg/m2, 1.75 mg/m2, or 2.33 mg/m2 dose of LB-100 or a salt thereof and a 1 mg/kg, 2 mg/kg, 3 mg/kg, 4 mg/kg, 5 mg/kg, 6 mg/kg, 7 mg/kg, 8 mg/kg, 9 mg/kg, or 10 mg/kg dose of an anti-programmed cell death protein-1 (anti-PD-1) antibody, wherein the LB-100 or salt thereof and the anti-PD-1 antibody are synergistically effective to treat the subject, wherein the treating is inducing inhibition, regression, or stasis of the cancer, and wherein the cancer is melanoma, colorectal cancer or glioblastoma.
|